| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
The present study was designated to evaluate the role of Epithelial cell adhesion molecule (EpCAM) in tumor resistance to chemotherapy in association with ovarian cancer stem cell.
To investigate whether the EpCAM-positive subpopulations enhance chemoresistance, ovarian cancer cells were exposed to cisplatin in vitro. Flow cytometric analysis showed that treatment with cisplatin result in enhanced expression of EpCAM in residual cells as compared to untreated cells. To evaluate the in vivo relevance of chemoresistance in EpCAM-positive cells, we studied an established mouse model in vivo, and we found that EpCAM-positive ovarian cancer cells are involved in resistance to chemotherapy. Given that a distinct subpopulation of EpCAM-positive cancer cells plays a critical role in chemoresistance, definitive treatment should target this subpopulation of EpCAM-positive cells in ovarian cancer.
|
